Wednesday, May 20, 2020


Don't let the current COVID-19 cautions stop your company's internal and vendor inspections / audits.  Learn remote approaches and tools to conduct successful cGMP compliance inspections / audits 100% remotely.  Check out my latest new webinar on:

CONDUCTING  REMOTE / VIRTUAL  CGMP INSPECTIONS  DURING  COVID-19 -

PER US FDA CGMPs and EU ISO  

at

https://jelincoln.com/GMPCourses.html

jel@jelincoln.com

Friday, May 15, 2020

Some of my upcoming webinars:


FDA CDS Software Regulation: The Latest Guidance on Clinical Decision Support Software 19-May, 2020 at 01:00 PM ET.
https://www.eventbrite.com/e/fda-cds-software-regulation-the-latest-guidance-on-clinical-decision-support-software-tickets-85457099485


Verification and/or Validation to meet US FDA CGMP and ISO 13485 Requirements 10-June, 2020 at 01:00 PM EST 
https://worldcomplianceseminars.com/webinardetails/799

How to Deploy Root Cause & CAPA to Minimize Human Error 24-June, 2020 at 01:00 PM ET

Medical Device Change Management 08-July, 2020 at 01:00 PM ET 
https://worldcomplianceseminars.com/webinardetails/849

jel@jelincoln.com
Questions / Answers from my recent IQ, OQ, PQ Webinar

1. Ques: when leveraging vendors' documentation, for example SAT testing leveraging into qualification, what are the main principles to be in place.

Ans:  Take your VMP requirements for the validation of that piece of equipment, subtract those SAT-satisfied tests, and develop test cases for the remainder, including any SAT tests that may be negatively impacted by actions upon the equipment since the SAT was performed, e.g., movement / transport, installation ... I've done this many times and had no push-back from regulatory agencies.  In fact it's specifically mentioned in ASTM E 2500 as an acceptable / preferred method.  

2.  Ques: what are the main principles with bracketing/family approach testing? 

Ans:  It would depend on the equipment family we're talking about (its complexity, inherent variability and end user risk).  As I mentioned in the webinar, I'm not much of a believer in Like-for-like, due to inherent variability in any equipment's manufacturing process.  But anything that is not (or minimally) subject to such variability, such as the equipment's software / firmware, in differing serial numbers of the same model of equipment, having the same software rev. no. / release no., could be considered, and those remaining / hardware elements, of minimal variability (based on data, or to a lesser degree, a priori considerations), if also low risk to the end user / patient, could be considered. 

Usually this "consideration" would mean that the validation of the 2nd , 3rd ... iteration of the "same" type of equipment, would be much reduced in possible number of test cases, number of elements in each test case,  reduced test case sample sizes (PQs), the numbers of PQs run, degree of repetitive descriptive documentation, etc., ... in subsequent validations compared to the first (of course, with cross-references in subsequent related validations to the initial validation).

In some / many cases the issue falls into a grey area, and it might be wise to validate, rather than try to develop a rationale and defend that rationale repeatedly with all stakeholders / inspectors, with the strong possibility after all that you could still lose the argument with a regulatory agency and have to validate anyway (been there, done that). 

jel@jelincoln.com  

Thursday, April 30, 2020

A Question on My Recent Webinar on Project Management for FDA Regulated Companies

Query : I'm an informally trained Project Management ... Now I am working on launching product and don't have FDA/EPA experience and we are launching product that falls under either regulation. Would this course (Project Management for FDA regulated companies) be of help?

Ans:  Definitely.  This course focuses on use of simple PM tools to drive FDA projects  (basically PM for the non-PM certified manager).  We cover 3 key tools:  the Gantt Chart (emphasized), the  CPM, and the PERT (with the last two considered for their network, and parallel path illustrative value); also discussing additional tools such as flow charts and cause and effect diagrams to assist in developing Milestones and Tasks.
The projects discussed with sample milestones / templates are:  
  • Design Control (21 CFR 820.30) / Design and Development Planning (ISO 13485:2016 7.3) for new device development; 
  • Product / Process / Equipment / Software Validation; 
  • Product Risk Management (ISO 14971); 
  • Use Engineering / Human Factors Engineering (IEC 62366-1:2015); 
  • Regulatory compliance inspection (Form 483) remediation.  

Due to the short length of the presentations, only the key milestones of each are listed / discussed, but that should be enough to start on the right path to use PM tools in those areas, fleshing out the tasks under the milestones by "reverse engineering", discussed in the webinar.  
Design Control does have an extensive Milestones / tasks listing, but most of the others only focus on Milestones.  
Though not discussed in the webinar, one could take the 21 "tabs" of the FDA's required 510(k) submission to develop the key Milestones for a 510(k) submission as well. 

jel@jelincoln.com

The 21 510(k) "tabs" have been added as project milestones discussed in subsequent versions of my Project Management webinars. - - JEL 09/20/2023

Tuesday, April 14, 2020

Key steps in the validation of the pharmaceutical manufacturing process per US FDA Guidance Document:

Process Validation Guidance Document (Pharma), US FDA,  Jan 2011
  • Stage 1 – Process Design
  • Stage 2 – Qualification
    • Part 1 – Facility Design
    • Part 2 – Qualification of Utilities & Equipment
      • Subsection 1 – Installation Qualification
      • Subsection 2 – Operational Qualification
      • Subsection 3 – Performance Qualification
    • Part 3 – Process Performance Qualification (PPQ)  
  • Stage 3 – Continued Process Verification (ongoing)

John E. Lincoln, jel@jelincoln.com

Friday, January 24, 2020

EO Sterilization Re-validation

If you perform an annual documentation / process review (review of past years' sterile load lot information), with no problems noted, documented, then the following is required every two years, assuming nothing in your process / product has had major changes:
The minimum re-validation requirements of ISO 11135-1:
  • Re-validate PCDs (verify that the ½ cycle BIs are more resistant than product bioburden);
  • Bioburden measurement (should be doing quarterly; no changes in average levels);
  • EO residuals (no subtle changes in product / process / packaging that could increase residuals)
  • 1 Half Cycle (verify overkill)
  • 1 Full Cycle (also used for the EO residuals testing); if acceptable / sterile, can be released for sale.
Also every two years, a full EO validation is required, e.g., 1st year:  Initial full validation, 2nd year:  If OK review, then abbreviated V&V (per above); 3rd year:  full validation; 4th year:  If OK review, then abbreviated V&V (per above); and so on.

John E. Lincoln               jel@jelincoln.com